Vexing vaccine delays hit drug firms
AstraZeneca and Pfizer are being attacked by the EU over what it claims are delays in delivering the Covid vaccine.

Drug companies AstraZeneca and Pfizer are being attacked by the EU over vaccine delivery delays that could slow the EU’s recovery from Covid-19, says Julia Horowitz on CNN. Pfizer’s problems look likely to be resolved soon, however, while AstraZeneca says “considerably fewer” doses will be supplied for some time. With AstraZeneca’s jab due to be approved by Europe’s regulator shortly, “mounting” anger means that Brussels and several countries are “threatening to take legal action and introduce export controls on doses produced in the bloc” (see page 8).
AstaZeneca’s announcement will prolong the “misery and pain” of Covid-19, says Aimee Donnellan on Breakingviews. Still, problems were “inevitable” as the vaccine, developed by the University of Oxford, is made “through a complicated biological process, requiring constant fine-tuning and vast 4,000-litre fermenters, which are in short supply”.
AstraZeneca’s problems are good news for the jab produced by Janssen, Johnson & Johnson’s European vaccine division, which the EU has pre-ordered in large amounts, says the Irish Times. Like the AstraZeneca jab, it doesn’t require “ultra-cold storage temperatures”; but unlike all its major competitors, it also involves a single injection, “greatly simplifying... a national vaccine rollout”. With trial data expected in the next few days, the vaccine is set to receive approval from the US Food and Drug Administration sometime in February, with the nod from the European Medicines Agency expected not long afterwards.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.

Matthew graduated from the University of Durham in 2004; he then gained an MSc, followed by a PhD at the London School of Economics.
He has previously written for a wide range of publications, including the Guardian and the Economist, and also helped to run a newsletter on terrorism. He has spent time at Lehman Brothers, Citigroup and the consultancy Lombard Street Research.
Matthew is the author of Superinvestors: Lessons from the greatest investors in history, published by Harriman House, which has been translated into several languages. His second book, Investing Explained: The Accessible Guide to Building an Investment Portfolio, is published by Kogan Page.
As senior writer, he writes the shares and politics & economics pages, as well as weekly Blowing It and Great Frauds in History columns He also writes a fortnightly reviews page and trading tips, as well as regular cover stories and multi-page investment focus features.
Follow Matthew on Twitter: @DrMatthewPartri
-
‘Inheritance tax insurance’ enquiries are soaring – but is it worth it?
Premiums for whole of life insurance can run to £5,000 a month to cover a £300,000 inheritance tax bill, with policies costing more the older you take them out.
-
MPs warn over Lifetime ISAs which could leave savers out of pocket
The Treasury Committee has highlighted confusion around the Lifetime ISA withdrawal charge, which risks consumers losing “a significant part of their savings”
-
Carson Block on short-selling and what investors should watch out for when going long
Interview Renowned short seller Carson Block talks to Matthew Partridge about his specialism and where to go long
-
Drinks maker Diageo gets back on its feet – should you invest?
Diageo has faced one disaster after another over the past two years. Is it finally time to buy?
-
Airtel Africa is dialling the right numbers – should you buy?
Opinion Mobile phone services group Airtel Africa is inexpensive and growing fast
-
The British railway industry is in rude health – here's why investors should jump aboard
The railway industry has bounced back from the devastating impact of the pandemic and is entering a new phase of development – and profitability
-
Infrastructure investing: a haven of stable growth amid market turmoil
From booming construction in emerging markets to digital and green transitions, the infrastructure sector offers security, returns and long-term opportunities
-
The costly myth of “sell in May”
Opinion May 2025's strong returns for US stocks have once again shown that putting too much weight on seasonal patterns will only make investors poorer, says Max King
-
Vietnam: a high-growth market going cheap
Opinion The threat of tariffs has shaken Vietnamese stocks, but long-term prospects remain solid, says Max King
-
Who’s driving Tesla?
As Elon Musk steps back from government with his eyes on the stars, investors ask if he’s still behind the wheel at his electric-car maker.